REPROCELL
David Bunton is an accomplished business leader with extensive experience in the life sciences sector. Currently serving as the CEO of REPROCELL Europe Ltd since July 2016, David oversees European operations following the merger of Biopta Ltd and Reinnervate Ltd. Additionally, David holds the position of Chairperson at the Precision Medicine Scotland Innovation Centre since May 2020. David founded and previously served as CEO of Biopta Inc. from January 2012 to September 2016 and was the CEO of Biopta Ltd from September 2002 to June 2016, providing non-clinical human tissue-based pharmacology services. Prior to these roles, David was a lecturer at Glasgow Caledonian University from April 1998 to September 2004. David's academic credentials include a PhD in Physiology from Glasgow Caledonian University and a degree in Physiology from the University of Glasgow, complemented by a management program at MIT Sloan School of Management in 2010.
This person is not in any offices
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.